Reports
Sale
Castrate-Resistant Prostate Cancer Market Size, Trends, Report: By Therapy Type: Hormonal Therapy, Immunotherapy, Chemotherapy, Others; By Therapy Drug Class: Antineoplastic, Non-steroidal Antiandrogen, Corticosteroids, Others; By Route of Administration; Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Castrate-Resistant Prostate Cancer Market Outlook
The castrate-resistant prostate cancer market size was valued at USD 11.19 billion in 2023, driven by the incidence of prostate cancer, along with development of new therapies globally. The market is expected to grow at a CAGR of 8.6% during the forecast period of 2024-2032, with the values likely to rise from USD 12.15 billion in 2024 to USD 23.50 billion by 2032.
Castrate-Resistant Prostate Cancer: Introduction
Castrate-Resistant Prostate Cancer (CRPC) is an advanced type of prostate cancer wherein the body stops responding to treatments. Prostate cancer is commonly treated by blocking the male sex hormone, testosterone, that promotes cancer cells growth. However, in the case of advanced castrate-resistant prostate cancer, the body stops reacting to hormone therapy.
CRPC can be metastatic or nonmetastatic. In metastatic CRPC (mCRPC), cancer spreads to other parts of the body. Common symptoms include pain while urinating, blood in urine, weight loss, fatigue, or shortness of breath. The treatment involves slowing the cancer growth and controlling the symptoms with the help of chemotherapy, immunotherapy, gene therapy and others.
In non-metastatic CRPC (nmCRPC), the cancer is only present in the prostate region.
Castrate-Resistant Prostate Cancer Market Analysis
Prostate cancer is the second most prominent cancer type in males affecting approximately 15.1% of the population. The treatment consists of radiation, chemotherapy, hormone therapy, targeted therapy, immunotherapy, and gene therapy. Hormone therapy is mostly preferred and constitutes treatments like androgen deprivation therapy (ADT), bilateral orchiectomy, LHRH agonists, androgen receptor (AR) inhibiting drugs such as Apalutamide, Darolutamide and Enzalutamide, and GnRH antagonists. Although these treatments have brought major improvements, there are several side effects one may experience with it. Hence, there has been extensive research in the domain fuelling castrate-resistant prostate cancer market value.
Radioligand therapy has gained attention of the scientists in the recent years. It sends radioactive emitters directly to the tumour associated targets. These radioactive atoms only target the DNA of cancer cells and provides an edge over the conventional external-beam radiation therapy, which cannot target the tumour cells directly. Currently, a combination of 177Lu-PSMA-617 with actinium-225 in conjunction to the J591 monoclonal antibody, is under first and second phase trials.
Molecular targeted therapy is another latest and advancing fields of CRPC treatment. In August 2024, FDA approved the combination of Enzalutamide (Xtandi) with Talazoparib (Talzenna) to treat metastatic Castrate-Resistant Prostate Cancer. Enzalutamide works by blocking hormones that accelerate cancer cell growth followed by Talazoparib, which blocks the activities of PARP (DNA repairing) protein. This makes cancer cell survival difficult. Talazoparib is the third PARP blocking drug to receive FDA approval. As a result, the castrate-resistant prostate cancer market growth is certain with the increasing research and development in oncology.
Castrate-Resistant Prostate Cancer Market Segmentation
Market Breakup by Therapy Type
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- Others
Market Breakup by Therapy Drug Class
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Market Breakup by Region- 7MM
- United States
- EU-4 and the United Kingdom
- Japan
Castrate-Resistant Prostate Cancer Market Overview
The North American territory dominates the castrate-resistant prostate cancer market share as it is the second leading cause of cancer death in the region. With the prevalence of a geriatric population and unhealthy lifestyle changes, the number of morbidities has grown in the area. Therefore, the government and key players of healthcare industry have taken strict measures to spread awareness about the disease in the relevant population. The presence of a proper infrastructure also enables the scientists to continue research for effective treatment.
The European territory along with Asia-pacific region can also observe a significant surge in the market, especially due to the efforts of the government and educational institutes to boost effective research and development. The Asian region being home world’s largest geriatric population can be a large market in the forecast period.
Castrate-Resistant Prostate Cancer Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Sanofi
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Astellas Pharma, Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Novartis AG
- Eli Lilly and Company
- Merck & Co., Inc.
- Allergan
- AstraZeneca
- Cipla Inc.
- Amneal Pharmaceuticals LLC
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy Type |
|
| Breakup by Therapy Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region- 7MM |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Castrate-Resistant Prostate Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Castrate-Resistant Prostate Cancer Epidemiology Analysis-7MM
5.1 Epidemiology Overview (2016-2031)
5.2 United States Castrate-Resistant Prostate Cancer Epidemiology (2016-2031)
5.3 EU-4 and United Kingdom Castrate-Resistant Prostate Cancer Epidemiology (2016-2031)
5.4 Japan Castrate-Resistant Prostate Cancer Epidemiology (2016-2031)
6 Castrate-Resistant Prostate Cancer Market Overview
6.1 Castrate-Resistant Prostate Cancer Market Historical Value (2017-2023)
6.2 Castrate-Resistant Prostate Cancer Market Forecast Value (2024-2032)
7 Castrate-Resistant Prostate Cancer Market Landscape
7.1 Castrate-Resistant Prostate Cancer: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Castrate-Resistant Prostate Cancer: Product Landscape
7.2.1 Analysis by Therapy Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
8 Castrate-Resistant Prostate Cancer Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Castrate-Resistant Prostate Cancer Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Castrate-Resistant Prostate Cancer Market Segmentation
11.1 Castrate-Resistant Prostate Cancer Market by Therapy Type
11.1.1 Market Overview
11.1.2 Hormonal Therapy
11.1.3 Immunotherapy
11.1.4 Chemotherapy
11.1.5 Others
11.2 Castrate-Resistant Prostate Cancer Market by Therapy Drug Class
11.2.1 Market Overview
11.2.2 Antineoplastic
11.2.3 Non-steroidal Antiandrogen
11.2.4 Corticosteroids
11.2.5 Others
11.3 Castrate-Resistant Prostate Cancer Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.4 Castrate-Resistant Prostate Cancer Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online Pharmacy
11.5 Castrate-Resistant Prostate Cancer Market by Region -7MM
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.4 Japan
12 United States Castrate-Resistant Prostate Cancer Market
12.1 U.S. Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)
12.2 U.S. Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)
12.3 Market Size by Therapeutic Class
13 EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market
13.1 EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)
13.2 EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)
13.3 Market Size by Therapeutic Class
14 Japan Castrate-Resistant Prostate Cancer Market
14.1 Japan Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)
14.2 Japan Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)
14.3 Market Size by Therapeutic Class
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Sanofi
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Johnson & Johnson Services Inc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Pfizer Inc.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Astellas Pharma, Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Bayer AG
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 F. Hoffmann-La Roche Ltd.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Mylan N.V.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Teva Pharmaceutical Industries Ltd.
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 GlaxoSmithKline plc
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Novartis AG
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Eli Lilly and Company
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Merck & Co., Inc.
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Allergan
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 AstraZeneca
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Cipla Inc.
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
21.16 Amneal Pharmaceuticals LLC
21.16.1 Financial Analysis
21.16.2 Product Portfolio
21.16.3 Demographic Reach and Achievements
21.16.4 Mergers and Acquisitions
21.16.5 Certifications
22 Castrate-Resistant Prostate Cancer - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 11.19 billion in 2023, driven preference for personalised medication to treat the rising cases of Castrate-Resistant Prostate Cancer.
The market is anticipated to grow at a CAGR of 8.6% during the forecast period of 2024-2032, likely to reach a market value of USD 23.50 billion by 2032.
The prevalence of Castrate-Resistant Prostate Cancer has increased, owing to lifestyle changes and high geriatric population. As a result, the market demand has seen a surge in the historical period.
There has been a significant development in targeted therapy to treat Castrate-Resistant Prostate Cancer. Recently FDA approved the combination of Enzalutamide (Xtandi) with Talazoparib (Talzenna) to stop cancer cell growth in the body. Radioactive pharmaceuticals like 177Lu-PSMA-617 are currently under clinical trial.
It can be treated through hormonal therapy, immunotherapy, chemotherapy, and others.
Patients can adopt either oral or parenteral method of treatment.
Antineoplastic, non-steroidal antiandrogen, corticosteroids and others commonly used to treat Castrate-Resistant Prostate Cancer.
The major regions of the market include United States, Japan, EU-4 and the United Kingdom.
The distribution channels include hospital, retail, and online pharmacies.
Key players involved in the market are Sanofi, Johnson & Johnson Services Inc., Pfizer Inc., Astellas Pharma, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., Allergan, Cipla Inc., and AstraZeneca.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER